By continuing to browse our site you agree to our use of cookies, revised Privacy Policy and Terms of Use. You can change your cookie settings through your browser.
I agree
Search Trends
SITEMAP
Copyright © 2024 CGTN. 京ICP备20000184号
Disinformation report hotline: 010-85061466
SITEMAP
Copyright © 2024 CGTN. 京ICP备20000184号
Disinformation report hotline: 010-85061466
An illustration of an esophageal cancer cell. /CFP
A group of Chinese scientists have developed an artificial intelligence (AI) platform that doubles the detection rate for early-stage esophageal cancer.
Esophageal cancer is often asymptomatic, but experienced clinicians can detect tumors and precancerous lesions with endoscopies. The five-year survival rate is over 90 percent when the tumor is treated during the early stages while the clinical outcomes sharply decline once patients start experiencing symptoms.
The study, published Thursday (BJT) in the journal Science Translational Medicine, introduces an architecture driven by deep learning algorithms, which are trained via datasets of more than 190,000 esophageal images gathered from several clinics in China.
A screenshot of the study published in the journal Science Translational Medicine, April 17, 2024.
The clinical trial, run by researchers from Taizhou Hospital in Zhejiang Province and Wuhan University's Renmin Hospital, recruited more than 3,000 participants who underwent endoscopies. The AI system was applied to half of the volunteers.
This platform effectively doubled the detection rate for high-risk esophageal lesions (1.8 percent) compared with that in the control group (0.9 percent), according to the study.
Also, the real-time AI tool has demonstrated a high sensitivity and specificity of 89.7 percent and 98.5 percent, respectively, in practical settings.
"The endoscopic assistance system, to a significant extent, enables endoscopists with less experience to enhance detection rates of high-risk esophageal lesions, thereby, reducing the frequency of missed diagnoses," said Mao Xinli, the corresponding author of the paper, from Taizhou Hospital.